MALVERN, Pa., March 21, 2022 (Globe NEWSWIRE) — Ocugen, Inc. (NASDAQ: OCGN), a medical-stage biopharmaceutical business centered on finding, acquiring, and commercializing gene therapies to treatment blindness disorders and developing a vaccine to help save lives from COVID-19, currently announced the appointment of Jessica Crespo, CPA, as Main Accounting Officer and Senior Vice President, Finance. She assumed the job helpful March 18, 2022.
In this part, she will be dependable for the development and execution of the Company’s economic technique, as perfectly as all corporate finance, accounting, and inside and external money reporting functions. She will provide as a member of Ocugen’s management team, reporting directly to the CEO.
Ms. Crespo has much more than 20 several years of practical experience in accounting and fiscal management. She has been with Ocugen considering that 2019, earlier serving as Vice President, Company Controller and Treasurer. Right before joining the Company, she held economic leadership roles in Aerie Pharmaceuticals, Aralez Prescribed drugs and Cubist Prescription drugs where she was dependable for monetary and technological accounting and SEC reporting, including the implementation of new accounting standards and the accounting and reporting of elaborate transactions. Prior to that, Ms. Crespo was a senior manager in Ernst & Young’s audit and assurance observe.
“Jess has been an critical member of the Ocugen team for almost three years and we are happy to recognize her precious contributions with this expansion of her job. The Enterprise has witnessed transformational growth around the past calendar year, as we work to advance the therapies in our pipeline towards regulatory acceptance. Jess’ awareness and skills will aid us sustain that momentum,” mentioned Dr. Shankar Musunuri, Chairman of the Board, Main Executive Officer, and Co-founder of Ocugen.
Ms. Crespo holds a Bachelor of Science in Accounting from Boston University and is a Licensed Community Accountant.
About Ocugen, Inc.
Ocugen, Inc. is a scientific-stage biopharmaceutical business focused on finding, building, and commercializing gene therapies to treatment blindness ailments and creating a vaccine to help you save life from COVID-19. Our breakthrough modifier gene remedy system has the opportunity to deal with several retinal disorders with one particular drug — “one to lots of,” and our novel biologic solution candidate aims to give better therapy to people with underserved disorders this sort of as damp age-linked macular degeneration, diabetic macular edema, and diabetic retinopathy. We are co-establishing Bharat Biotech’s COVAXIN™ vaccine prospect for COVID-19 in the U.S. and Canadian marketplaces. For extra data, make sure you stop by www.ocugen.com.
Cautionary Take note on Forward-Wanting Statements
This press launch includes ahead-looking statements within just the indicating of The Personal Securities Litigation Reform Act of 1995, which are subject matter to threats and uncertainties. We may perhaps, in some circumstances, use conditions this sort of as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should” or other terms that convey uncertainty of future activities or results to identify these forward-on the lookout statements. This kind of statements are issue to several important elements, hazards and uncertainties that may possibly trigger true occasions or results to vary materially from our recent expectations. These and other risks and uncertainties are a lot more fully explained in our periodic filings with the Securities and Exchange Commission (“SEC”), together with the possibility things described in the part entitled “Risk Factors” in the quarterly and once-a-year stories that we file with the SEC. Any ahead-hunting statements that we make in this push release converse only as of the day of this push launch. Except as essential by law, we think no obligation to update ahead-searching statements contained in this press release whether or not as a final result of new details, foreseeable future gatherings or if not, following the date of this press launch.
Head, Trader Relations & Communications